- |||||||||| carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - Nov 18, 2024
P=N/A, N=19, Completed,
Recruiting --> Completed | N=40 --> 19 | Trial completion date: Feb 2025 --> Apr 2024 | Trial primary completion date: Feb 2025 --> Apr 2024
- |||||||||| Rytary (levodopa/carbidopa extended-release capsule) / Amneal
Enrollment change, Trial withdrawal: Novel Non-opioid Post-surgical Pain Treatment in Females (clinicaltrials.gov) - Mar 17, 2024
P2, N=0, Withdrawn,
Recruiting --> Completed | N=40 --> 19 | Trial completion date: Feb 2025 --> Apr 2024 | Trial primary completion date: Feb 2025 --> Apr 2024 N=60 --> 0 | Recruiting --> Withdrawn
- |||||||||| carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
Trial completion date, Trial primary completion date: Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - Nov 8, 2023
P=N/A, N=40, Recruiting,
N=60 --> 0 | Recruiting --> Withdrawn Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025
- |||||||||| Rytary (levodopa/carbidopa extended-release capsule) / Amneal
Trial completion date, Trial primary completion date: Novel Non-opioid Post-surgical Pain Treatment in Females (clinicaltrials.gov) - Feb 8, 2023
P2, N=60, Recruiting,
Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025 Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
- |||||||||| carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
Trial completion date, Trial primary completion date: Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - Dec 5, 2022
P=N/A, N=40, Recruiting,
Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Feb 2023 --> Feb 2024 | Trial primary completion date: Feb 2023 --> Feb 2024
- |||||||||| levodopa/carbidopa orally disintegrating tablets / Generic mfg.
Observational data, Journal: Impact of the COVID-19 Pandemic on Patients with Parkinson's Disease from the Perspective of Treating Physicians-A Nationwide Cross-Sectional Study. (Pubmed Central) - Mar 26, 2022
The Parkinson's Disease during the COVID-19 Pandemic (ParCoPa) survey was conducted as an online, nationwide, cross-sectional survey from December 2020 to March 2021 and aimed to assess the impact of the pandemic on the medical care of PD patients from the physicians' perspective...Participants offered alternative consultation options, mostly in the form of telephone (77.5%) or online (64.1%) consultations, but telephone consultations were the most accepted by patients ("broadly accepted", 40.0%). We identified pandemic-related deficits in providing care for patients with PD and areas of improvement to ensure continued care for this vulnerable patient population.
- |||||||||| levodopa/carbidopa orally disintegrating tablets / Generic mfg.
COVID-19 PANDEMIC AND PARKINSON’S DISEASE: IMPACT ON PATIENT CARE AND DISEASE BURDEN IN GERMANY () - Mar 9, 2022 - Abstract #ADPD2022ADPD_1943;
Our analysis raises awareness that medical care for PD patients is significantly compromised in the pandemic. Telemedicine approaches and measures to minimize the risk of infection during outpatient visits may be appropriate to adequately treat this vulnerable patient population in the context of this and future pandemic situations.
- |||||||||| carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
Trial primary completion date: Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - Dec 21, 2021
P=N/A, N=40, Recruiting,
Telemedicine approaches and measures to minimize the risk of infection during outpatient visits may be appropriate to adequately treat this vulnerable patient population in the context of this and future pandemic situations. Trial primary completion date: Feb 2022 --> Feb 2023
- |||||||||| Rytary (levodopa/carbidopa extended-release capsule) / Amneal
Enrollment open: Novel Non-opioid Post-surgical Pain Treatment in Females (clinicaltrials.gov) - Nov 18, 2021
P2, N=60, Recruiting,
Trial primary completion date: Feb 2022 --> Feb 2023 Not yet recruiting --> Recruiting
- |||||||||| carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
New trial: Vigor and the LDR in Parkinson Disease (clinicaltrials.gov) - Mar 29, 2021
P, N=40, Recruiting,
- |||||||||| carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
Enrollment change, Trial termination: Vision Response to Dopamine Replacement (clinicaltrials.gov) - Jun 12, 2019
P2, N=20, Terminated,
Not yet recruiting --> Recruiting N=50 --> 20 | Recruiting --> Terminated; Lack of funding
- |||||||||| carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse (clinicaltrials.gov) - Sep 27, 2017
P2, N=131, Completed,
N=50 --> 20 | Recruiting --> Terminated; Lack of funding Recruiting --> Completed | N=90 --> 131 | Trial primary completion date: Aug 2017 --> Jan 2017
- |||||||||| Apokyn (apomorphine bolus injection) / Stada, Supernus Pharma, Aguettant
Enrollment change: Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT) (clinicaltrials.gov) - Apr 24, 2014
P4, N=129, Completed,
Recruiting --> Completed | N=90 --> 131 | Trial primary completion date: Aug 2017 --> Jan 2017 N=100 --> 129
- |||||||||| carbidopa/levodopa / Generic mfg., levodopa/carbidopa orally disintegrating tablets / Generic mfg.
New P2 trial: Vision Response to Dopamine Replacement (clinicaltrials.gov) - Aug 12, 2012
P2, N=50, Recruiting,
|
